Slonim CB, Foster S, Jaros M, et al. - In a pooled analysis from 2 randomized, double-masked, placebo-controlled, multicenter phase 3 clinical trials, researchers tested the safety and effectiveness of oxymetazoline hydrochloride, 0.1%, ophthalmic solution (oxymetazoline, 0.1%) in candidates with acquired ptosis. Oxymetazoline, 0.1%, or vehicle, self-administered as a single drop per eye, once daily, for 42 days was given to candidates (randomized 2:1). The sample consisted of 304 participants (mean [SD] age, 63.8 [13.8] years; 222 women [73%]). According to findings, oxymetazoline, 0.1%, was correlated with better results and was well tolerated after instillation at days 1 and 14 in phase 3 trials, showing its potential promise for the treatment of acquired ptosis, although more research is required to elucidate the clinical relevance of these findings after 6 weeks.